NCT02053298View on ClinicalTrials.gov

Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Open Angle Glaucoma
Interventions
DRUG

Timolol & Dorzolamide

Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month

Trial Locations (1)

3000 Leuven

University Hospitals Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT02053298 - Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients | Biotech Hunter | Biotech Hunter